1. Introduction {#s1}
===============

The prevalence of heart failure (HF) is rapidly increasing, and it is a common cause of hospitalization and death. Hospitalization of older patients can lead to functional deterioration resulting in disability and dependency.[@b1] The prognosis, risk of rehospitalization, and functional deterioration in HF are mainly evaluated by clinical, laboratory and echocardiographic parameters. The common end point of all these parameters in the elderly HF patient is frailty---a subject of interest which is becoming an increasingly high-priority topic in cardiovascular medicine due to aging. Therefore, frailty is thought to be one of the strong prognostic markers of HF. Frailty is defined as a geriatric syndrome resulting in impaired resistance to stressors (such as illness, surgery, etc.) due to a decline in physiologic reserve.[@b2] The degree of frailty is determined by old age, associated comorbidities, and disability.[@b3]--[@b5] The decline in physiologic reserve is mainly a consequence of involvement of organ systems.

Frailty is considered to be a high-risk state predictive of a range of adverse health outcomes.[@b6] One of the most important clinical applications of using frailty is to predict risk of morbidity and mortality of cardiovascular diseases in the elderly. Frailty and cardiovascular diseases share common biological pathways including chronic low grade inflammation.[@b7] Chronic inflammation results in oxidation of lipoproteins and activation of atheromatous plaques, and acitvates catabolic states especially in the skeletal muscles causing redistribution of amino acids from the musculature.[@b8],[@b9] As frailty involves multisystem physiologic dysregulation, it is conceivable that chronic inflammation contributes to frailty through its detrimental effects on other physiologic organ systems, such as musculoskeletal and endocrine systems, anemia, clinical and subclinical cardiovascular diseases, and nutritional dysregulation.[@b10] Therefore, there is a close association between frailty, inflamation and cardiovascular diseases.

The main objective of our study was to define cardiovascular risks, comorbidities, and frailty in patients aged ≥ 65 years with HF, and to evaluate the prognostic significance of frailty in these patients.

2. Methods {#s2}
==========

We included patients aged ≥ 65 years with the diagnosis of HF treated at Cukurova University Hospital, Cardiology Department. The clinical and laboratory data, echocardiography and ECGs were collected and recorded. Additionally, the frailty score of the patients was evaluated by Canadian Study of Health and Aging (CSHA) frailty scoring system.[@b11] Furthermore, the impact of combined comorbid conditions were quantified according to coronary artery disease (CAD)-specific index.[@b12] All the scoring systems were evaluated by two cardiologists and one internist separately, and the final scores were recorded upon agreement. The CSHA frailty scale is a 7-point scale of frailty with a good prognostic value depending on clinical judgement. The patients are considered to be frail if the score is ≥ 5. CAD-specific index is a valuable way of evaluation of the impact of combined comorbidity on the clinical status. In this scoring system, each separate major comorbidity (current smoker, hypertension, history of cerebro-vascular event, diabetes mellitus with complications, chronic obstructive pulmonary disease, peripheral vascular disease, tumor, renal disease, metastatic cancer) has a coefficient, and final score is calculated by the sum of the coefficients. The patients are considered to be at low to moderate risk if the score is 0--3, and high risk if it is ≥ 4.

Patients were followed-up for upto six months.The clinical data, history of hospitalization and death due to progressive HF were recorded in each visit or during hospitalization. The patients without admission during study follow-up period were phone called, and the relevant data were gathered by telephone interview. The major clinical outcomes were death due to progressive HF and combined hospitalization and death due to progressive HF. All the patients enrolled in the study signed written informed consent. The patients who were not willing to participate in the study, and with insufficient clinical information were excluded. The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guidelines. The study was was approved by the local ethic committee.

For each continuous variable, normality was checked by Kolmogorov Smirnov and Shapiro-Wilk tests and by histograms. Comparisons between groups were applied using the student *t* test for normally distrubited data, and Mann Whitney *U* test was used for the data not normally distrubited. All the categorical variables were analyzed by Pearson\'s chi-squared test or Fisher\'s exact test as appropriate. Univariate analysis was performed to assess the association between death and/or hospitalization due to progressive HF and the possible risk factors including age, sex, hypertension, diabetes, hyperlipidemia, smoking, accompanying comorbidities, echocardiographic findings, and frailty score. Logistic regression models were constructed for assessing the independent effect of frailty score on death and/or hospitalization due to progressive HF. The results were presented as odd ratios (OR) and their 95% confidence intervals, as mean ± SD and as *n* (%). A *P* value \< 0.05 was considered as significant.

3. Results {#s3}
==========

We included 86 patients aged ≥ 65 years with the diagnosis of HF. Baseline characteristics, laboratory data, echocardiographic parameters and frailty scores were compared between the groups ([Table 1](#jgc-15-11-675-t01){ref-type="table"}). The median follow-up time was four months (min: 2, max: 6 months). There was 50 male, and 36 female patients in the whole group. The mean age was 75 ± 6.5 years. Of these 86 patients, 17 (19.7%) patients encountered an event (death and combined death and/or hospitalization). Nine patients (10.4%) died during follow-up. Seven patients were hospitalized more than once. As a comorbidity, 3 patients had malignant diseases, 2 of those with malignancy died during an episode of hospitalization due to decompensation of HF. Thirty patients (34.9%) were considered frail according to CSHA frailty score. When we compared frail and non-frail patients determined according to CSHA, the groups were similar with respect to age, distribution of gender, body mass index, blood pressure, pulse pressure, heart rate, laboratory data with the exception of total protein and albumin levels. Total protein and albumin levels were found to be lower in frail patients (Total protein level: 6.8 ± 0.6 g/dL in nonfrails, 6.5 ± 0.9 g/dL in frails, *P* = 0.05; albumin level: 3.8 ± 0.4 g/dL in nonfrails, 3.4 ± 0.6 in frails, *P* = 0.001). Regarding echocardiographic findings, left atrium was larger, and ejection fraction (EF) was lower in frail group, although statistically nonsignificant (left atrial diameter: 40.2 ± 6.1 mm in nonfrails, 42.8 ± 6.3 mm in frails, *P* = 0.072; EF: 49.5% ± 13.8% in nonfrails, 43.6% ± 13.6% in frails, *P* = 0.064). The CAD-specific index was also similar between the groups (3.13 ± 2.8 points in nonfrails, 4.13 ± 3.31 points for frails, *P* = 0.139).

###### Comparison of the the baseline characteristics, laboratory and echocardiographic parameters and frailty scores according to the end points.

  Frailty                                Death and/or hospitalization due to progressive heart failure   Death due to progressive heart failure                                                
  ------------------------------------- --------------------------------------------------------------- ---------------------------------------- -------------- -------------- --------------- -----------
  Gender, Female/Male                                             41.2%/58.8%                                         42.0%/58.0%                    0.949       55.6%/44.4%     40.3%/59.7%      0.379
  Age, yrs                                                        73.5 ± 6.5                                           75.4 ± 6.4                    0.258        75.3 ± 6.7     75.0 ± 6.5       0.921
  Hypertension                                                       82.4%                                               81.2%                       0.910          77.8%           81.8%         0.768
  Diabetes mellitus                                                  35.3%                                               24.6%                       0.374          22.2%           27.3%         0.746
  Smoking history                                                    47.1%                                               50.3%                       0.773          33.3%           52.0%         0.526
  CAD                                                                58.8%                                               46.4%                       0.358          66.7%           46.8%         0.258
  COPD                                                               35.3%                                               31.9%                       0.788          33.3%           32.5%         0.958
  Chronic renal disease                                              35.3%                                               13.0%                     **0.030**        33.3%           15.6%         0.184
  Stroke history                                                     17.6%                                               11.6%                       0.503          22.2%           11.7%         0.371
  PAD                                                                  0                                                  2.9%                       0.478            0             2.6%          0.625
  Dementia                                                           58.8%                                               52.2%                       0.254          44.4%           54.5%         0.812
  Anemia                                                             23.5%                                               23.2%                       0.976          33.3%           22.1%         0.449
  Liver disease                                                      11.8%                                                1.4%                     **0.038**        11.1%           2.6%          0.188
  Malignancy history                                                 11.8%                                                1.4%                     **0.038**        22.2%           1.3%        **0.001**
  NYHA functional class                                            3.1 ± 0.9                                           2.4 ± 1.1                   **0.012**      3.4 ± 0.9       2.4 ± 1.0     **0.006**
  BMI, kg/m^2^                                                    27.8 ± 9.4                                           27.3 ± 5.0                    0.729        26.0 ± 5.4     27.6 ± 6.1       0.677
  Heart rate, beats/min                                           81.3 ± 16.9                                         73.6 ± 13.5                    0.092       81.7 ± 16.5     74.3 ± 14.2      0.258
  Pulse pressure, mmHg                                            47.6 ± 10.0                                         48.1 ± 11.8                    0.921        44.2 ± 7.8     50.0 ± 20.0      0.324
  Hb, mg/dL                                                       12.3 ± 1.9                                           12.4 ± 1.7                    0.879        11.6 ± 1.9     12.4 ± 1.6       0.280
  Creatinine, mg/dL                                                1.2 ± 0.6                                           1.1 ± 0.6                     0.645        1.2 ± 0.8       1.1 ± 0.6       0.994
  Uric acid, mg/dL                                                 7.1 ± 1.9                                           6.7 ± 1.7                     0.401        7.2 ± 1.7       6.7 ± 1.7       0.455
  Total protein, g/dL                                              6.3 ± 0.7                                           6.8 ± 0.7                   **0.035**      6.3 ± 0.7       6.7 ± 0.7       0.188
  Albumin, g/dL                                                    3.3 ± 0.6                                           3.7 ± 0.5                   **0.014**      3.1 ± 0.7       3.7 ± 0.5     **0.014**
  Left atrial diameter, mm                                        42.5 ± 7.9                                           40.7 ± 5.8                    0.497        42.0 ± 7.5     41.0 ± 6.2       0.876
  Ejection fraction                                              37.5% ± 9.7%                                        49.9% ± 13.8%                 **0.001**     36.4% ± 8.8%   48.7% ± 13.9%   **0.012**
  Left ventricular diastolic size, mm                             54.9 ± 14.3                                          50.7 ± 7.4                    0.328       57.5 ± 18.1     50.7 ± 7.5       0.326
  Left ventricular mass, g                                       279.1 ± 100.3                                        257.7 ± 74.7                   0.749       289.5 ± 94.2   258.7 ± 76.7      0.662
  ASA                                                                64.7%                                               73.9%                       0.448          55.6%           74.0%         0.242
  Beta blocker                                                       47.1%                                               50.7%                       0.787          22.2%           53.2%         0.078
  ACEI or ARB                                                        47.1%                                               59.4%                       0.356          33.3%           59.7%         0.130
  Aldosterone antagonist                                             29.4%                                               11.6%                       0.066          22.2%           14.3%         0.529
  Statin                                                             41.2%                                               40.6%                       0.964          44.4%           40.3%         0.809
  Calsiyum antagonist                                                  0                                                 20.3%                     **0.042**          0             18.2%         0.162
  Alpha blocker                                                      5.9%                                                 4.3%                       0.788          11.1%           3.9%          0.331
  Furosemide                                                         70.6%                                               46.4%                       0.074          77.8%           48.1%         0.091
  Digoxin                                                            17.6%                                               15.9%                       0.865          22.2%           15.6%         0.610
  Frailty score (CSHA)                                             5.5 ± 1.2                                           3.8 ± 1.3                  **\< 0.001**    5.7 ± 1.3       3.9 ± 1.4     **0.002**
  CAD-specific index score                                         4.9 ± 3.7                                           3.1 ± 2.7                   **0.021**      6.3 ± 4.4       3.1 ± 2.6     **0.006**

ACEI: angiotensin-converting-enzyme inhibitor; ARB: angiotensin II receptor blockers; ASA: asetilsalisilik asit; BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; CSHA: Canadian Study of Health and Aging; Hb: hemoglobin; PAD: peripheral artery disease.

In patients reaching an endpoint, the prevelance of chronic renal disease, liver disease, malignancy, NYHA functional class, frailty score and CAD-specific index were found to be significantly higher and albumin levels, EF were found to be significantly lower than the group without death and/or hospitalization due to progressive HF ([Table 1](#jgc-15-11-675-t01){ref-type="table"}).

The patients who encountered an event (death and combined death and/or hospitalization due to progressive HF) were categorized and compared according to their age (65--79 and ≥ 80 years), ejection fraction (EF ≥ 40 % and EF \< 40%), functional capacity \[New York Heart Association (NYHA) I-II and NYHA III-IV\], and frailty (score ≥ 5 and \< 5) ([Table 2](#jgc-15-11-675-t02){ref-type="table"}). Reduced EF (\< 40%) is associated with significantly higher risk for combined death and/or hospitalization due to progressive HF \[14 (40%) *vs*. 3 (5.9%), *P* \< 0.001\] and higher risk for death due to progressive HF \[7 (20%) *vs*. 2 (3.9%), *P* = 0.017). High NYHA group (III and IV) is associated with significantly higher risk for both end points \[12 (31.6 %) *vs*. 5 (10.4 %), *P* = 0.014 for combined end points, 7 (18.4%) *vs*. 2 (4.1%), *P* = 0.032 for death due to HF\]. Higher CAD-specific index is associated with significantly higher risk for death and/or hospitalization due to HF group \[11 (31.4%) *vs*. 6 (11.8%), *P* = 0.024\] and death due to HF group \[7 (20%) *vs*. 2 (3.9%), *P* = 0.017\]. Similar results are seen on CSHA frailty index. Higher CSHA frailty score is associated with increased death and/or hospitalization and death due to progressive HF \[14 (46.7%) vs. 3 (5.4%), *P* \< 0.001 and 8 (26.7%) vs. 1 (1.8), *P* \< 0.001\] ([Table 2](#jgc-15-11-675-t02){ref-type="table"}).

###### Univariate analysis of major prognositic parameters in HF patients.

                        Death and/or hospitalization due to progressive HF   Death due to progressive HF                                                                                                  
  -------------------- ---------------------------------------------------- ----------------------------- ------------ -------------------- -------------- ----------- ------------ --------------------- --------------
  Age, yrs                                     ≥ 80                                   5 (18.5%)            22 (81.5%)    0.89(0.27--2.83)       0.844       4 (14.8%)   23 (85.2%)    1.87 (0.46--7.63)       0.373
  65--79                                    12 (20.3%)                               47 (79.7%)             5 (8.7%)        54 (91.3%)                                                                    
  NYHA                                        III-IV                                 12 (31.6%)            26 (68.4%)   3.97(1.26--12.55)     **0.014**     7 (18.4%)   31 (81.6%)   5.19 (1.01--26.67)     **0.032**
  I-II                                      5 (10.4%)                                43 (89.6%)             2 (4.1%)        46 (95.9%)                                                                    
  EF (%)                                    EF \< 40%                                 14 (40%)              21 (60%)    10.67(2.77--41.07)   **\< 0.001**   7 (20.0%)    28 (80%)    6.13 (1.19--31.53)     **0.017**
  EF ≥ 40%                                   3 (5.9%)                                48 (94.1%)             2 (3.9%)        49 (96.4%)                                                                    
  CAD-specific index                        High risk                                11 (31.4%)            24 (68.6%)   3.43(1.13--10.42)     **0.024**     7 (20.0%)    28 (80%)    6.13 (1.19--31.25)     **0.017**
  Low-moderate risk                         6 (11.8%)                                45 (88.2%)             2 (3.9%)        49 (96.4%)                                                                    
  Frailty (CSHA)                             Present                                 14 (46.7%)            16 (53.3%)   15.46(3.94--60.62)   **\< 0.001**   8 (26.7%)   22 (73.3%)   20.0 (2.36--169.05)   **\< 0.001**
  Absent                                     3 (5.4%)                                53 (94.6%)             1 (1.8%)        55 (98.2%)                                                                    

CAD: coronary artery disease; CSHA: Canadian Study of Health and Aging; EF: ejection fraction; HF: heart failure; NYHA: New York Heart Association.

When we compared the aforementioned risk factors by multivariate analysis, CSHA frailty score ≥ 5 is significantly associated with death due to progressive HF for short term follow-up (OR = 17.41; 95% confidence interval (CI): 1.32--228.82, *P* = 0.030). Reduced EF (\< 40%) (OR = 15.63; 95% CI: 2.67--91.36, *P* = 0.002), CAD-specific index (OR = 5.85; 95% CI: 1.17--29.33, *P* = 0.032) and CSHA frailty score ≥ 5 (OR = 26.18; 95% CI: 3.72--184.15, *P* = 0.001) are significantly associated with death and/or hospitalization due to progressive HF ([Table 3](#jgc-15-11-675-t03){ref-type="table"}).

###### Comparison of the the risk factors according to the end points by multivariate analysis.

                                     Death due to progressive heart failure   Death and/or progressive hospitalization due to heart failure                                                              
  --------------------------------- ---------------------------------------- --------------------------------------------------------------- -------------- ----------- --------- ------- -------------- -----------
  Age ≥ 80 yrs                                       0.558                                                1.75                                 0.31--9.77      0.525     --0.824   0.44     0.09--2.19      0.316
  Male                                               0.597                                                1.82                                0.32--10.17      0.497     --0.217   0.81     0.17--3.88      0.786
  NYHA functional capacity III-IV                    0.626                                                1.87                                0.19--18.54      0.593      1.086    2.96    0.46--19.19      0.255
  EF \< 40 %                                         1.751                                                5.76                                0.81--41.19      0.081      2.749    15.63   2.67--91.36    **0.002**
  CAD-specific index ≥ 4                             1.795                                                6.02                                0.90--40.06      0.063      1.766    5.85    1.17--29.33    **0.032**
  Frailty score (CSHA) ≥ 5                           2.857                                                17.41                               1.32--228.82   **0.030**    3.265    26.18   3.72--184.15   **0.001**

CAD: coronary artery disease, CSHA: Canadian Study of Health and Aging, EF: ejection fraction, NYHA: New York Heart Association.

4. Discussion {#s4}
=============

The main finding of our study is the demostration of frailty to be one of the most powerful risk predictors of death and/or hospitalization due to progressive HF. Our prospective cohort study addresses the importance of classifying elderly HF patients according to their frailty status to predict the development of important health outcomes during short term follow-up.

Along with the increase in life expectancy of the general population, the number of critically elderly ill patients increases. However, the survival of very old age group is still rather poor.[@b13],[@b14] In addition, HF is characterized by a frequent instability, and until now the factors determining the rehospitalization of decompensated HF patients are not completely identified.

The frailty has been defined as a clinical state of increased vulnerability from age-associated decline in physiological reserves and functions in a wide range of physiological systems.[@b15] The identification of frailty in patients with HF is important from the clinical point of view, as this condition exerts unfavorable effects on the course of HF. The American Heart Association, American College of Cardiology and the Society of Geriatric Cardiology have emphasized the role of frailty in cardiovascular diseases.[@b16] In our study, we demonstrated that reduced EF (\< 40%), being NYHA III and IV and high CSHA frailty score were associated with significantly higher risk in death and/or hospitalization due to progressive HF.

All of our study population had a substantial proportion of heart failure patients which may have increased the mean frailty score in this cohort, and may influence the generalizability of our results. This study was not designed to make recommendations about routine frailty screening. Frailty is common end point for most of the chronic diseases, and also because frailty may result in chronic inflammation, hypothetically it may cause disease progression. So, it is chicken and egg paradox.

It is worth noting that in our study, high risk in CAD-specific index is associated with higher risk for death and/or hospitalization due to progressive HF and death due to progressive HF. Frailty occurs in 25%--50% of patients with cardiovascular diseases depending on the measurement scale of frailty. Besides, frail patients with cardiovascular diseases, especially those undergoing invasive methods such as PCI, are more likely to have more adverse effects than people without frailty.[@b17]

In many previous studies, it is found that the intensive care unit (ICU) mortality range changes from 14% to 46% and hospital mortality range changes from 28% to 48%.[@b13],[@b18] Using a frailty index, one study found a strong association between increased frailty and 90-day mortality.[@b19] In a Canadian study, a lower index on a frailty scale was independently associated with increased survival in 610 patients followed for 12 months.[@b20] A recent multi-centre American study found an association between greater degree of frailty, measured with the Clinical Frailty Scale and higher risk of mortality.[@b21] We also showed frailty to be strongly associated with mortality and combined outcome of death and hospitalization. This finding is compatible with the evidence demonstrating the prognostic role of frailty.[@b22] The CSHA frailty scoring system is easy to classify frailty status, and it is adequate for clinical practice. Our findings demonstrate the feasibility of using the CSHA in the HF patient population. Also, we think that this simple-to-use clinical frailty scale should be a component risk for evaluation of elderly HF patients.

End-organ disease such as HF exacerbates frailty. It is unclear, however, if frailty itself can contribute to organ dysfunction and resultant HF. One study found that in community-dwelling individuals, moderate and severe frailty have an increased risk of incident heart failure diagnosis.[@b23] While there is no direct relationship between frailty and severity of HF, there is evidence that frailty is more common with acute decompensated HF as compared to those with preserved and reduced EF.[@b24]

In our study, we also found that high NYHA functional class (III and IV) was associated with significantly higher risk for death and/or hospitalization due to HF and death due to progressive HF. Dunbar, *et al*.[@b25] have demonstrated that HF patients with high frailty score had worse NYHA functional class indicating the high clinical severity of the condition. Therefore, it seems that a deterioration of functional capabilities and an increase in symptom severity naturally lead to increased frequency of hospitalization in HF.

The relationship between inflammation and frailty is complex since both linearly increase with advancing old age.[@b26] Frail participants have a higher presence of concomitant factors like disability, medical conditions that could increase the inflammatory parameters. Studies have shown that elevated cellular and molecular inflammatory mediators have inverse associations with levels of albumin.[@b27] In our study, we found a relation between death and/or hospitalization and low albumin level. This result may reflect the relationship between inflammation and frailty. Also, there is growing evidence suggesting that nutrition is important and a modifiable factor potentially affecting the frailty status of the older person. It is evident that nutritional interventions may potentially improve the older person\'s risk profile by improving fraility status.[@b28]

Frailty is generally considered to be a geriatric syndrome. Individuals with chronic diseases, such as chronic kidney disease (CKD), may be at risk for premature frailty. Some studies reported a high prevalence of frailty among elderly individuals with mild to moderate CKD. They concluded that CKD may be a major contributor to the development of frailty.[@b29] In our study, CKD was found to be significantly higher in group with combined endpoint of death and/or hospitalization due to progressive HF.

In our study, we found an association between death and/or hospitalization and malignancy history. In the literature, prevalence of frailty and pre-frailty in older cancer patients is high.[@b30] Routine assessment of frailty in older cancer patients may have a role in guiding treatment. Failure to detect frailty potentially exposes older cancer patients to treatments from which they might not benefit, and indeed may be harmed.

There were some limitations in this study. Although it is a prospective study, our results came from a single center with relatively small number of patients. Therefore, a larger sample size study would allow other independent variables in the regression analysis to examine the relation between frailty and clinical outcomes. We did not have a control group from the general population of our hospital and we have no long-term survival outcome data in our study. This was not within the scope of the study. In our study, only salt restriction diet (less than 5000 mg/day) was applied and no other protein-related diet program was applied. Also, the chosen way of measuring frailty is subjective and may have a higher inter-rater variability than more objective measures of frailty. In our study, we did not provide a treatment protocol specifically for fragility. We have just applied the heart failure routine treatment algorithm.

In conclusion, high frailty score in elderly HF patients is valuable to predict major adverse outcomes, particularly death and hospitalization due to progressive HF. Future studies are required to more precisely clarify the role of frailty in prognosis of HF, and improve management of patients depending on their frailty status.
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